NSAID-Derived Selenazoles/Thiazoles as Potential Cancer Therapeutics

Penn State University Background
Pancreatic cancer is one of the deadliest cancers, with a median survival of less than one year and a five year survival rate of less than 10%. Most patients do not have symptoms in earlier stages – 80% of pancreatic cancers are metastatic at the time of diagnosis. Given this dire prognosis, AS-10 may address a significant unmet need, aiming to improve outcomes for advanced pancreatic cancer patients through the use of a novel, small molecule therapeutic compound as a monotherapy or in combination with the current standard of care.
Technology Overview
A cyclic Se-Aspirin compound, AS-10, was identified through extensive SAR studies focused on Se-NSAID hybrid compounds based on potency determination, toxicity, and drug-likeness. AS-10 is selectively toxic to cancer cells in vitro, demonstrating high efficacy across different PDAC cell lines at 48h, with IC50 ranging from 0.7-2.5 µM compared to Gemcitabine (Gem), which has an IC50 >500 µM. AS-10 inhibits tumor growth without apparent systemic toxicity by inducing apoptosis in various cancer cells, especially PDAC. Experimental evidence shows a synergistic effect with Gem observed both in cell culture and xenograft mouse models in both male and female mice.
Stage of Development

Technology Readiness Level (TRL): 4-7
Continue preclinical activities, including formulation/dosing regimen to be used in vivo, PK/PD, tox and efficacy determination.

Related Blog

Smart, interactive desk

Get ready to take your space management game to the next level with the University of Glasgow’s innovative project! By combining the

Mechanical Hamstring™

University of Delaware Technology Overview This device was created to allow athletes who suffer a hamstring strain to return to the field

Join Our Newsletter

                                                   Receive Innovation Updates, New Listing Highlights And More